Regulatory flexibility and early conversations allowed COVID-19 vaccine candidates to move to market quickly and should remain in place as next generation products enter the development process, sponsors said.
Angela Hwang, group president of Pfizer Inc.’s Biopharmaceuticals Group, said “the fit-for-purpose way of looking at what is the...







